These results suggested that plasmatic levels of HSP90α at diagnosis is a favorable predictor for PFS and OS in advanced lung cancer patients treated with PD-1/PD-L1 inhibitors plus chemotherapy. The gene discussed is HSP90AA1; the disease is lung carcinoma.